Lacosamide

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Epilepsy With Partial-onset Seizures

Conditions

Epilepsy With Partial-onset Seizures

Trial Timeline

Jun 5, 2015 → May 28, 2020

NCT ID

NCT02477839

About Lacosamide

Lacosamide is a phase 3 stage product being developed by UCB for Epilepsy With Partial-onset Seizures. The current trial status is completed. This product is registered under clinical trial identifier NCT02477839. Target conditions include Epilepsy With Partial-onset Seizures.

What happened to similar drugs?

20 of 20 similar drugs in Epilepsy With Partial-onset Seizures were approved

Approved (20) Terminated (6) Active (0)

✅ZonegranEisaiApproved

✅Perampanel + PlaceboEisaiApproved

✅perampanelEisaiApproved

✅Perampanel Oral TabletEisaiApproved

✅PerampanelEisaiApproved

✅zonisamide low dose group + zonisamide high dose groupEisaiApproved

✅Zonisamide at targeted daily doses of 100-500 mg/day + Placebo administered to match targeted daily doses of 100-500 mg/dayEisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03559673	Pre-clinical	Completed	—	—	Epilepsies, Partial
NCT04627285	Phase 3	Completed	Dec 28, 2020	Feb 12, 2025	Epilepsy
NCT02710890	Phase 2/3	Completed	May 30, 2017	Jun 28, 2019	Epilepsy
NCT02582866	Phase 3	Completed	Jan 1, 2016	Jan 1, 2020	Epilepsy
NCT02477839	Phase 3	Completed	Jun 5, 2015	May 28, 2020	Epilepsy With Partial-onset Seizures
NCT02124564	Phase 3	Completed	Apr 1, 2014	Nov 21, 2017	Epilepsy
NCT01969851	Phase 2	Completed	Feb 13, 2014	Apr 10, 2018	Epilepsy
NCT01921205	Phase 3	Completed	Aug 29, 2013	Jan 24, 2017	Epilepsy
NCT01724918	Phase 2	Terminated	May 1, 2013	Aug 1, 2016	Focal Epilepsy
NCT01832038	Phase 3	Completed	Mar 26, 2013	Jul 31, 2019	Epilepsy
NCT01673282	Pre-clinical	Completed	Jul 1, 2012	Jul 1, 2015	Focal Epilepsy With and Without Secondary Generalization
NCT01530386	Phase 1	Completed	Jan 1, 2012	Jul 1, 2012	Healthy Subjects
NCT01484977	Phase 3	Completed	Dec 1, 2011	Dec 1, 2013	Epilepsy
NCT01236001	Pre-clinical	Completed	Sep 1, 2010	Mar 1, 2012	Seizures
NCT01118962	Phase 2	Completed	Aug 1, 2010	Oct 1, 2012	Epilepsy
NCT01235403	Approved	Completed	Jun 1, 2010	Dec 1, 2011	Partial Epilepsies
NCT01118949	Phase 2	Completed	May 1, 2010	Aug 1, 2011	Epilepsy
NCT00938431	Phase 2	Completed	Nov 1, 2009	Aug 1, 2014	Epilepsy
NCT00955357	Approved	Completed	Aug 1, 2009	Aug 1, 2013	Partial Epilepsies
NCT00771927	Pre-clinical	Completed	Oct 1, 2008	Mar 1, 2012	Epilepsies, Partial

Competing Products

20 competing products in Epilepsy With Partial-onset Seizures

See all competitors

Product	Company	Stage	Hype Score
perampanel	Eisai	Phase 2	35
Lacosamide	UCB	Phase 3	40
Zonisamide + Placebo	Eisai	Phase 3	32
Zonegran	Eisai	Approved	35
perampanel + perampanel	Eisai	Phase 1	29
Perampanel + Placebo	Eisai	Approved	35
perampanel	Eisai	Approved	35
E2007 + Placebo	Eisai	Phase 2	35
Placebo + Rufinamide	Eisai	Phase 3	40
E2007 (perampanel) + Placebo	Eisai	Phase 2	35
Perampanel Oral Tablet	Eisai	Approved	43
perampanel	Eisai	Phase 3	40
Perampanel	Eisai	Pre-clinical	26
Zonisamide + Carbamazepine	Eisai	Phase 3	40
Perampanel	Eisai	Approved	43
Perampanel and Microgynon-30 + Perampanel and Microgynon-30	Eisai	Phase 1	29
Perampanel	Eisai	Phase 2	35
Zonisamide + Placebo	Eisai	Phase 3	40
zonisamide low dose group + zonisamide high dose group	Eisai	Approved	43
E2007 + E2007 + Placebo	Eisai	Phase 2	35